Véronique Guerin‐Meyer

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study

Julien Edeline, M. Benabdelghani, Aurélie Bertaut et al. · Journal of Clinical Oncology · 2019 · 504 citations

Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions

Laurence Gamelin, M. Boisdron‐Celle, R. Delva et al. · Clinical Cancer Research · 2004 · 342 citations · Full text

Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803

Olivier Bouché, Jean‐Luc Raoul, Franck Bonnetain et al. · Journal of Clinical Oncology · 2004 · 278 citations · Full text

Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage

Érick Gamelin, M. Boisdron‐Celle, Véronique Guerin‐Meyer et al. · Journal of Clinical Oncology · 1999 · 204 citations

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach

M. Boisdron‐Celle, Olivier Capitain, Roger Faroux et al. · Seminars in Oncology · 2017 · 78 citations

Preclinical Drug Evaluation, Pharmacology, Toxicology +7